Clinical Trials Directory

Trials / Completed

CompletedNCT06059027

Microbes and Respiratory Illnesses

Microbes and Respiratory Illnesses, The MARI Study

Status
Completed
Phase
Study type
Observational
Enrollment
290 (actual)
Sponsor
University of Wisconsin, Madison · Academic / Other
Sex
All
Age
4 Years – 12 Years
Healthy volunteers
Accepted

Summary

This study is called the Microbes and Respiratory Illnesses (MARI) Study. Children growing up on farms are exposed to many types of microbes that could be beneficial. It is thought that increased exposure to certain types of microbes early in life helps to develop a healthy immune system and reduce the risk for severe common cold illnesses, breathing problems, and allergies.

Detailed description

Respiratory viruses, most notably rhinoviruses (RV), commonly infect school-age children during the month of September and are a well-known exposure for asthma exacerbations. Allergic sensitization is a risk factor for increased viral respiratory illness burden and wheezing. Nasal Airway Epithelial Cell (NAEC) responses to viral exposure show distinct transcriptional programs that differ in individuals with allergies or asthma. There is a growing body of evidence strongly suggesting nasal airway microbial communities enriched in several commensal bacteria are associated with protection from symptomatic RV infections. Metagenomic sequencing from previously collected nasal samples obtained at age 2 years showed distinct microbial communities and function in the Traditional agrarian (TA) Community Cohort compared to farm and non-farm children. How the early life nasal microbial community can impact risk for viral respiratory infection symptoms and NAEC biology remains an important and unresolved question. To address this important question, this proposal includes an observational study to identify patterns of nasal airway gene expression among three cohorts of school-age children that markedly differ in their susceptibility to respiratory illnesses and wheezing: children from TA/Amish communities, suburban children without asthma, and suburban children with asthma.

Conditions

Timeline

Start date
2023-10-18
Primary completion
2025-11-06
Completion
2025-11-06
First posted
2023-09-28
Last updated
2026-01-16

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT06059027. Inclusion in this directory is not an endorsement.